HArmonyCa™ is often associated with two claims: immediately visible volume and longer-term stimulation of tissue. That summary sounds straightforward, but it leaves important questions unanswered. Which change was studied? How many people took part? Was there a control group? And which reactions occurred after injection? An informed decision therefore depends not only on the proposed mechanism, but also on the quality of the available evidence.
In a medical aesthetics consultation at PRECIOUS in Wiesbaden, the first step should be to define the specific goal: is the concern volume, contour, skin quality or a combination? These goals are not interchangeable. Facial anatomy, medical history, previous treatments and willingness to accept uncertainty matter as well. A brand name cannot replace that assessment and guarantees neither a natural appearance nor a particular duration.
What is HArmonyCa™?
HArmonyCa™ is an injectable hybrid product that combines hyaluronic acid with calcium hydroxyapatite, abbreviated as CaHA. Hyaluronic acid is used in aesthetic medicine as a gel-like filler material. CaHA consists of mineral microspheres suspended in a carrier gel. The combination is intended to unite an immediate shaping effect with a later tissue response. This describes the mechanism, not the outcome for an individual patient.
The term hybrid filler can suggest that two substances must automatically be better than one. Clinically, that conclusion is too simple. The relevant question is whether the desired goal fits the properties of the product at all. Volume deficit, a fine superficial line and a concern about skin structure call for different considerations. The facial region and tissue plane also influence which method may be appropriate.
What roles do hyaluronic acid and CaHA play?
The hyaluronic acid component contributes to initial shape and volume. CaHA is associated with a later change in tissue properties. Small prospective studies have observed increased dermal thickness or changes in elastography measurements after treatment. Such measurements can support a biological effect, but they do not automatically show how visible the change will be in everyday life or how an individual person will judge it.
The time course should not be treated as a fixed clock either. Frequently quoted timelines for collagen formation come from particular study protocols and measurement methods. They cannot be transferred into a personal calendar. Skin, subcutaneous tissue, baseline findings and treatment plans differ. A responsible consultation therefore separates what a study observed on average from what can be expected in one individual treatment.
What do studies of HArmonyCa™ show?
A prospective open-label post-marketing study examined 140 adults with moderate to severe midface volume deficit. The cheek and optionally the jawline were treated, and a touch-up was possible after two weeks. Participants were followed for twelve months. After one month, 82.8 per cent improved by at least one grade on the volume scale used in the study. Other investigator-rated and patient-reported measures also remained improved during follow-up.
These results are relevant, but the study was not blinded and had no randomised untreated control group. It therefore cannot clearly separate the contributions of the product, injection technique, participant selection and the assessment setting. Disclosed conflicts of interest also matter: several authors were employed by the manufacturer and another author acted as a consultant. This does not make the data worthless, but it belongs in their interpretation.
An earlier prospective study involving 15 people compared treated and untreated sides of the face over 120 days. Sonographically measured dermal thickness increased significantly on the treated side after 90 and 120 days, and both participants and clinicians rated the aesthetic result positively. The small sample, single centre and short period limit how widely the findings can be applied. The study supports a measurable effect, but it does not answer a general question about the best filler.
- Does the population studied resemble my baseline concern?
- Was the product compared with another treatment or with no treatment?
- Did the study assess visible outcomes, measurements or both?
- How long was follow-up, and who funded or supported the study?
How does HArmonyCa™ differ from other fillers?
A pure hyaluronic acid filler is selected mainly for its shaping and volumising properties. A product containing CaHA combines that objective with a possible longer-term tissue response. Other biostimulators use different materials and mechanisms again. This does not create a simple ranking. The more useful question is which concern is being treated and whether the risk profile fits the intended effect.
Reversibility also belongs in the comparison. Hyaluronic acid can in principle be broken down with hyaluronidase. A hybrid product additionally contains a CaHA component that cannot be dissolved in the same way. It is therefore especially important to discuss the goal, amount, region and alternatives clearly beforehand. The term hybrid means more than two proposed mechanisms; it also means that the properties of both components need to be considered.
Which questions determine suitability?
Suitability begins with a realistic description of the goal. A general wish for rejuvenation is too broad for that purpose. It is more useful to identify which contour or loss of tissue is concerning, which change is desired and which change is explicitly not wanted. Photographs from different periods may show how the face has changed, but they replace neither examination nor informed consent.
- What specific aesthetic goal is being pursued?
- Which previous fillers, operations or skin treatments have been performed?
- Which medicines, allergies and medical conditions are relevant?
- Which alternative would be less invasive or easier to correct?
The answer may also be that another method or no injection is the more appropriate decision. Dynamic lines, volume loss and changes in skin surface do not arise from the same mechanism. A treatment that may suit a contour concern is therefore not necessarily the right answer to a fine line or a pigmentation change. Good advice makes that distinction visible.
Which risks belong in the consultation?
In the open-label study of 140 adults, 95.7 per cent experienced at least one mild or moderate injection-site reaction. The most common treatment-related adverse events were injection-site pain in 11.4 per cent, an injection-site mass in 10.7 per cent and headache in 7.1 per cent. These figures come from that particular study protocol and are not a prediction for an individual patient.
In addition to temporary reactions, filler injections can cause serious vascular complications. A systematic analysis of 243 published cases described skin ischaemia after vascular occlusion and, when the ophthalmic arterial territory was involved, neuro-ophthalmic injury. A case-based review cannot determine how often such events occur. It does show why anatomical expertise, an emergency plan and an immediate response to unusual symptoms are essential safety issues.
Anyone who notices sudden, unusual or increasing symptoms after an injection should not wait for a routine follow-up appointment, but seek medical contact immediately. Before treatment, it should also be clear who can be reached outside practice hours and what the emergency pathway is. Safety is not limited to sterile technique; it includes patient selection, technique, consent, follow-up and clear responsibility if a complication occurs.
How can you prepare for the consultation?
- Write down the specific goal and what should remain unchanged.
- Bring details of previous fillers, treatment dates and known products.
- Prepare an up-to-date list of medicines, supplements, allergies and medical conditions.
- Ask about alternatives, reversibility, follow-up and the plan for complications.
PRECIOUS is a private practice for internal medicine, longevity and aesthetic medicine in Wiesbaden. Billing is private according to the German medical fee schedule, GOÄ. For an aesthetic consultation, a complete history is more useful than selecting a product before the appointment. Contact is possible by telephone, WhatsApp or email, and online booking is available around the clock.
The consultation should make room not only for desired outcomes, but also for uncertainty and limitations. Useful questions include: how will a good result be recognised? What change would be too much? How will the treatment be documented? When will follow-up occur? And which options exist if the result does not match expectations? These questions offer more protection than a general promise of a natural result.
How can HArmonyCa™ be assessed realistically?
HArmonyCa™ combines two established material principles in one product. Prospective studies report improvements in volume deficits and measurable changes in dermal thickness. At the same time, the studies assessed here lack randomised comparisons with other fillers or with no treatment. The data therefore demonstrate neither a superior product nor a guaranteed outcome.
A reasoned decision emerges when the goal, anatomy, evidence, alternatives and risks align. Starting with a brand name begins at the wrong end. A better opening question is: which change is medically and aesthetically reasonable, and which method can pursue it with an acceptable balance of potential benefit, uncertainty and burden?
Sources
- Gritti et al.: prospective open-label post-marketing study of a hyaluronic acid and CaHA hybrid injectable, PubMed PMID 40948024.
- Bravo et al.: prospective clinical and sonographic study of dermal thickness and aesthetic change, PubMed PMID 37334389.
- Sito et al.: systematic analysis of published cases of filler-induced facial ischaemia, PubMed PMID 36477154.

